MED-EL Cochlear Implant
Med-El Corp. · Decision date Jan 23, 2026
What did the FDA approve?
FDA records P000025/S137 as a supplement to PMA P000025, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jan 23, 2026.
FDA approval order statement
The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) supplement, which requested approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P000025/S134 Based upon the information submitted, the PMA supplement is approved.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Ear, Nose, Throat
- Decision date
- Jan 23, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P000025/S137
- Regulatory pathway
- PMA supplement
- Applicant
- Med-El Corp.
- Product code
- MCM
- Decision code
- APPR
- Decision date
- Jan 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, cochlear.
- Applicant
- Med-El Corp.
- Product code
- MCM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P000025. Subsequent supplements may change the device or its indications.
FDA decision timeline
P000025 · Original PMA
COMBI 40+ COCHLEAR IMPLANT SYSTEM
P000025/S134 · Related supplement
MED-EL CI System
P000025/S137 received
Application receipt date recorded by FDA.
P000025/S137 · FDA decision
Normal 180 Day Track No User Fee
P000025/S136 · Related supplement
MED-EL Cochlear Implant System
Timeline entries are records held by MedtechLedger for P000025. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P000025
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Med-El Corp. | PMA approval | Aug 20, 2001 | FDA | |
MED-EL CI SystemP000025/S134 | Med-El Corp. | PMA supplement | Nov 26, 2025 | FDA |
MED-EL Cochlear Implant SystemP000025/S136 | Med-El Corp. | PMA supplement | Oct 9, 2026 | FDA |
Explore the linked device profile
Other records with product code MCM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Nucleus 22 Cochlear Implant SystemP840024/S099 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
Nucleus 22 Cochlear Implant SystemP890027/S067 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
Nucleus 24 Cochlear Implant SystemP970051/S244 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
CLARION MULTI-STRATEGY COCHLEAR IMPLANTP960058/S178 | Advanced Bionics | PMA supplement | Sep 18, 2026 | FDA |
HiResolution Bionic Ear SystemP960058/S177 | Advanced Bionics | PMA supplement | Sep 4, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Med-El Corp.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Furstenweg 77a, Innsbruck, 6020
Sources and methodology
- Original FDA record: P000025/S137
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



